About Naomi Patel, MD

Naomi Patel is a practicing adult rheumatologist and clinical researcher. Dr. Patel is a graduate of the David Geffen School of Medicine at the University of California, Los Angeles. She completed her Internal Medicine internship, residency, and chief resident year at Stanford and then completed her rheumatology fellowship at Massachusetts General Hospital and pursued a Master of Public Health degree through the Harvard T. H. Chan School of Public Health. She enjoys seeing and working with patients in the Rheumatology Clinic with a variety of rheumatic diseases, with a specialization in vasculitis. With >50 peer-reviewed publications in the medical literature, Dr. Patel receives grant funding to conduct research in quantifying and assessing the impact of glucocorticoids in rheumatic diseases. She also serves as an Investigator in different clinical trials and conducts clinical epidemiologic research evaluating the impact of rheumatic diseases and immunosuppressive medications on the outcomes of COVID-19 infection and post-acute sequelae of COVID-19. She is an active member and participant in the American College of Rheumatology and its subcommittees.

Departments, Centers, & Programs:

Clinical Interests:

Treats:

Locations

Mass General Rheumatology
55 Fruit St.
Yawkey Center for Outpatient Care
Suite 4B
Boston, MA 02114
Phone: 617-726-7938

Medical Education

  • , David Geffen School of Medicine @ UCLA
  • Residency, Stanford University Medical Center
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Internal Medicine, American Board of Internal Medicine
  • Rheumatology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Dr. Patel conducts research in several areas including: 1) evaluating the comprehensive impact of glucocorticoids and their impact on quality-of-life and healthcare resource utilization in rheumatic diseases. She is the Principal Investigator of a prospective cohort with ongoing enrollment to address these questions, 2) Evaluating the impact of rheumatic diseases and immunosuppressive medications on the outcomes of COVID-19 infection and post-acute sequelae of COVID-19, 3) Multiple clinical trials in which she has served as an Investigator. Her research has been funded by grants from the Rheumatology Research Foundation.

Publications

Reviews: Comments and Ratings